One clinical trial involved treatment of four patients with solid tumors (1 of which was a CRC patient) with TAS266, a nanobody that targets death receptor 5 (DR5), a cell surface receptor that triggers apoptosis [34]. This evidence concerns the gene TNFRSF10B and colorectal carcinoma.